IDG and Nature Reviews Drug Discovery Target Watch
Researchers supported by the IDG program will work with Nature Reviews Drug Discovery (NRDD) to develop new content on a regular basis highlighting understudied protein targets. Read the articles below to learn more about the IDG program and new proteins of interest.
- PKN3: a target in cancer metastasis
September 14, 2022
- Novel drug targets in 2021
March 31, 2022
- eEF2K: an atypical kinase target for cancer
July 13, 2021
- PIKfyve: a lipid kinase target for COVID-19, cancer and neurodegenerative disorders
September 9, 2021
- BCKDK: an emerging kinase target for metabolic diseases and cancer
June 11, 2021
- Novel drug targets in 2020
April 6, 2021
- CDC42BPA/MRCKα: a kinase target for brain, ovarian and skin cancers
February 8, 2021
- WNK kinases: an untapped opportunity to modulate ion transport
November 6, 2020
- HCAR3: an underexplored metabolite sensor
October 2, 2020
- STK19: a new target for NRAS-driven cancer
June 25, 2020
- KNa1.1 channels as a target for treating early-onset epilepsy
May 13, 2020
- PIP5K1A: a potential target for cancers with KRAS or TP53 mutations
April 24, 2020
- Novel drug targets in 2019
April 9, 2020
- GPR84: An immune response dial?
February 20, 2020
- PKMYT1: A forgotten member of the WEE1 family
November 26, 2019
- ADCK3/COQ8a: The choice target of the UbiB protein kinase-like family
September 16, 2019
- TRIC-B: an under-explored druggable ion channel
July 26, 2019
- RIOK2:Straddling the kinase/ATPase line
June 26, 2019
- CDK16: the pick of the understudied PCTAIRE kinases
May 21, 2019
- Novel drug targets in 2018
March 26, 2019
This page last reviewed on February 17, 2023